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OBJECTIVE — To assess whether providing customized clinical information to patients and
physicians improves safety or quality of diabetes care.
RESEARCH DESIGN AND METHODS — Study subjects included 123 primary care
physicians and 3,703 eligible adult diabetic patients with elevated A1C or LDL cholesterol, who
were randomly assigned to receive customized feedback of clinical information as follows: 1)
patient only, 2) physician only, 3) both the patient and physician, or 4) neither patient nor
physician. In the intervention groups, patients received customized mailed information or phy-
sicians received printed, prioritized lists of patients with recommended clinical actions and
performance feedback. Hierarchical models were used to accommodate group random
assignment.
RESULTS — Study interventions did not improve A1C test ordering (P  0.35) and nega-
tively affected LDL cholesterol test ordering (P  0.001) in the 12 months postintervention.
Interventions had no effect on LDL cholesterol values (P  0.64), which improved in all groups
over time. Interventions had a borderline unfavorable effect on A1C values among those with
baseline A1C 7% (P  0.10) and an unfavorable effect on A1C values among those with
baseline A1C 8% (P  0.01). Interventions did not reduce risky prescribing events or increase
treatmentintensiﬁcation.Timetonextvisitwaslongerinallinterventiongroupscomparedwith
that for the control group (P  0.05).
CONCLUSIONS — Providing customized decision support to physicians and/or patients
did not improve quality or safety of diabetes care and worsened A1C control in patients with
baseline A1C 8%. Future researchers should consider providing point-of-care decision sup-
portwithredesignofofﬁcesystemsand/orincentivestoincreaseappropriateactionsinresponse
to decision-support information.
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D
espite recent improvements in glu-
cose, blood pressure, and LDL cho-
lesterol(LDL)controlinadultswith
diabetes (1), 15% of adults with diabe-
tes were simultaneously at the goal for
these three critically important compo-
nents of care as recently as 2007 (2). Re-
search studies document substantial
ongoing problems with safety of diabetes
care as well. Risky prescribing events are
common and may occur in 12% of
adults with diabetes annually (3). Errors
of omission, deﬁned as failure to intensify
pharmacotherapy when indicated, affect
30–65% of adults with diabetes (4).
Only 30% of U.S. physicians cur-
rently have access to comprehensive out-
patient electronic medical records
(EMRs) (5). However, many medical
groups have electronic laboratory, diag-
nosis, and/or pharmacy databases that
can be used to generate reminders and
suggestions for future care based on re-
sults of past actions. In general, informa-
tion feedback is most effective in altering
behavior when it is tailored (customized)
to the conditions on which performance
is based (6). Simple outcome feedback is
only weakly related to improvements in
performance across a variety of complex
problem-solving and decision-making
tasks (7,8). Feedback to physicians has
been shown to be most effective in bring-
ing about change in physician behaviors
whenitiskeyedtoclearlyidentiﬁedcom-
ponents in speciﬁc diagnostic and patient
management tasks (9,10). On the patient
side, the capacity to make decisions is en-
hancedwhen1)patientsaregivenspeciﬁc
information regarding their progress in
achievingspeciﬁchealthoutcomesand2)
this information is discussed with their
health care providers (11).
Few studies have assessed the effec-
tiveness of coordinated interventions tar-
getedsimultaneouslytophysiciansandto
their patients. However, a Cochrane col-
laborative review of strategies to improve
diabetes care reported that interventions
that combine patient components with
other components (physician or organi-
zation of care) are the most potent inter-
vention strategies (12). One classic study
(13)showedin1985thatcoordinatedpa-
tient and physician interventions were
more effective than those aimed at one or
the other group. Limits of that study in-
cluded a very expensive intervention
modelandthefactthatA1Cfellonlyfrom
11 to 10%. A more recent report of a co-
ordinated patient and physician interven-
tion (14) showed that intensive (and very
expensive), noncustomized feedback to
patients and their physicians reduced
A1C by 0.5% (to 8.3%). Importantly, the
coordinated feedback strategy was ac-
ceptable to physicians. However, in that
intervention, most physicians received
feedback on only one of their patients, so
it did not take advantage of transfer of
learning by physicians to other patients
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on multiple patients (15).
Based on these and other consider-
ations, we hypothesized that a potent in-
tervention to improve quality and safety
of diabetes care in the absence of EMRs
would be to extract clinical data from au-
tomated databases and provide clinical
decision support guided by past patient-
speciﬁc physician actions with coordi-
nated interventions targeted to their
patients. For this purpose, we developed
anapproachtoimprovediabetescarethat
was designed to encourage both patient
activation and guide physician intensiﬁca-
tion of therapy. Customized interventions,
such as the automated one described here,
are simple and inexpensive and have the
potential of being acceptable to most pa-
tients, while ﬁtting easily into routine pri-
mary care practice settings.
RESEARCH DESIGN AND
METHODS
Hypothesis
This clinic-randomized trial was designed
to assess whether feedback of speciﬁc clini-
cal information to patients only, physicians
only, or both patients and their physicians
improved quality or safety of diabetes care
compared with that for a usual-care control
group with no intervention.
Study setting and study subjects
This study was conducted from 2002 to
2005 at HealthPartners Medical Group
(HPMG), a Minnesota multispecialty
medical group providing care to 7,000
adults with diagnosed diabetes at 18 clin-
ics. At HPMG most diabetes care is pro-
vided by primary care physicians (PCPs)
with support from diabetes educators.
Approximately 10% of diabetic patients
were seen by an endocrinologist or endo-
crinenurseclinicianeachyear,mostoften
for a single visit. Approximately 30% of
diabetic patients had an encounter with a
diabetes teaching nurse or dietitian each
year, most often for a single one-on-one
visit. Additional data on the study popu-
lation have been published previously
(16).
The study included all HPMG PCPs
providing ongoing care to at least 10
adults with diabetes in 2001. The study
included all patients of study PCPs who
met the study criteria for diagnosis of di-
abetes in a 12-month time period: two or
more ICD-9 diagnosis codes for diabetes
or a ﬁlled prescription for a diabetes-
speciﬁc drug. This method of diabetes
identiﬁcation has an estimated sensitivity
of 0.91 and positive predictive value of
0.94 in the study population (17).
Deﬁnition and measurement of
variables: glycemic and lipid control
All A1C tests at HPMG were done at one
accredited clinical chemistry laboratory
using a standard high-pressure chroma-
tography assay method (18) with a coef-
ﬁcient of variation of 0.058% at A1C of
8.8%. There were no changes in the assay
method during the study period. Direct
assays of total cholesterol, HDL choles-
terol, and triglycerides (minimum 10 h
fast) were done using standard assay
methods at the same laboratory with LDL
cholesterol calculated using the Friede-
wald equation only if triglycerides were
400 mg/dl. All A1C and LDL choles-
terol values and test dates were recorded
foradeﬁned12-monthperiodbeforeand
a 12-month period after the date of the
ﬁrst intervention. If multiple A1C or LDL
cholesterol tests were done within a pe-
riod, the most recent value was analyzed.
Quality and safety of diabetes care
We classiﬁed patients as receiving high-
qualityandsafemedicalcareiftheyeither
achieved A1C and LDL cholesterol goals
with no inappropriate pharmacotherapy
orwereabovetheA1CorLDLcholesterol
goal but received appropriate pharmaco-
therapy within 4 months. Appropriate
pharmacotherapy was deﬁned as initia-
tion of therapy, an increase in doses of
appropriately chosen agents, or addition
of an appropriately chosen agent in re-
sponse to A1C or LDL cholesterol values
above goal. Dose increases for speciﬁc
glycemic control agents and lipid control
agents were assessed based on dose in
milligrams per day, as calculated for each
drug for each patient. Insulin titration
could not be assessed because of limited
data in pharmacy databases.
Inappropriate pharmacotherapy in-
cluded reducing dose or withdrawing
medications,failingtointensifytreatment
when A1C or LDL cholesterol were above
the goal, or risky prescribing events in-
cluding the following: 1) use of met-
formin in a patient with congestive heart
failure (ICD-9 code 428) or with creati-
nine 1.5 mg/dl or alanine aminotrans-
ferase (ALT) 4  normal; 2)u s eo f
thiazolidinediones in a patient with con-
gestive heart failure or ALT 2.5  nor-
mal;3)useofastatininapatientwithALT
4  normal; or 4) use of both a statin
and ﬁbrate in a patient with creatine
phosphokinase 2  normal.
Other variables
Patient data extracted from computerized
databasesincludedage,sex,A1CandLDL
cholesterol values, coronary artery dis-
ease status based on ICD-9 and Current
Procedural Terminology, 4th edition,
codes,eligibilityforglucoseorlipidinter-
vention,creatininelevels,andmedication
prescriptions ﬁlled.
Description of interventions
Customized physician intervention.
Physicians received a printed list of their
diabetic patients every 4 months. Patients
were prioritized based on distance from
A1C or LDL cholesterol goal, and the list
included patient laboratory data, medica-
tions, comorbidity, and renal function.
Decision-support feedback included in
the list to each physician focused on one
or more of the following for each patient:
1. Reminders for overdue A1C or LDL
cholesterol tests.
2. Recommendation to intensify phar-
macotherapy if A1C or LDL choles-
terol was above the goal and there was
no treatment intensiﬁcation in the
prior 4 months.
3. Notiﬁcation of inappropriate pharma-
cotherapy. If patients were receiving
any potentially risky treatments, a
speciﬁc alternative treatment was
suggested.
Performance feedback was also provided
every 4 months to physicians receiving
this intervention. Feedback ranked each
provider on the percentage of their dia-
betic patients at the goal relative to other
physicians in their clinic and in the med-
ical group.
Customized patient intervention. Pa-
tients assigned to this intervention who
werenotatthegoalforeitherA1CorLDL
cholesterol received a mailed customized
4-page brochure every 4 months that in-
cluded the following components:
1. A summary of the patient’s current
condition. A graph showed personal
trendsinA1CandLDLcholesterolval-
ues over at least a 12-month period
and noted that the patient was above
the goal for A1C, LDL cholesterol or
both.
2. General medication recommenda-
tions. Patients were encouraged to see
their physician soon and were given a
customized checklist of items to dis-
cuss with him or her, including the
following: a) if the patient was taking
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cotherapy was suggested; b) if the pa-
tient was receiving pharmacotherapy,
adjustment of therapy was suggested;
and c) if inappropriate pharmacother-
apy was identiﬁed, caution and a dis-
cussion with the physician were
suggested.
3. Outline of the beneﬁts of decisions
(and behaviors) to reduce A1C or LDL
cholesterol.
No incentives were provided to either pa-
tients or providers to take recommended
actions.Nospeciﬁctrainingwasprovided
to clinics other than a brief explanation to
participating physicians advising collabo-
ration with their nurses and each clinic’s
diabetes educator in pursuing recom-
mended therapeutic actions. EMR tech-
nology was not used to generate or
providediabetesclinicaldecisionsupport
during this study.
Plan of analysis
Preintervention patient characteristics
were compared across the four study
groups using logistic regression, a general
linear model, or a Kruskal-Wallis test, as
appropriate,toidentifycharacteristicsnot
equally distributed after group random-
ization. Three planned contrasts identi-
ﬁed intervention groups that differed
from the control group. The hypothesis
that interventions improved care was
tested using general (normal error distri-
bution and identity link function) or gen-
eralized (binomial error and logit link)
linear mixed regression models (19).
Postintervention outcomes were pre-
dicted from physician and patient inter-
ventionmaineffectsandtheirinteraction,
a set of covariates (i.e., age, sex, preinter-
vention test values [A1C or LDL choles-
terol], coronary artery disease status,
insulin use, and glucose or lipid interven-
tion eligibility), and signiﬁcant covariate-
by-intervention parameters to estimate
and describe intervention effects that
were different across patient groups.
Three planned contrasts were used to
compare each intervention group with
the control group. All analyses were per-
formedusingSASversion9.0(20.05)
and were limited to patients with preran-
domization A1C 7% or LDL cholesterol
100 mg/dl who were enrolled 1 year
before and after the intervention. With
N  123 providers and an average of 30
eligible patients per physician and
assuming intraclass correlation coefﬁ-
cientphysician  0.01–0.05, the analysis
was poweredtodetectstandardizedeffect
sizesofd0.11–0.14forthemaineffects
and d  0.15–0.20 for the interaction
and, for binary outcomes, main effect in-
creases of 0.07–0.10 relative to 0.30 (or
0.70) and for interaction effects of 0.10–
0.14 relative to 0.35.
Protection of human subjects
This study was reviewed, approved in ad-
vance, and monitored by the HealthPart-
ners Institutional Review Board (project
01-053).
RESULTS— Table 1 shows a compar-
ison of baseline characteristics of study
subjects in each intervention group. Be-
cause the study was randomized at the
clinic level, it was not surprising to ﬁnd
somebaselinepatientcovariateimbalance
across groups. These data guided covari-
ate adjustment in subsequent analyses.
Table2showsthatA1CandLDLcho-
lesterol improved in all groups during the
study period. Among the n  3,702 pa-
tients with a preintervention A1C test,
A1C test rates were signiﬁcantly lower in
the three intervention groups (Mpt 
Table 1—Description of patients and physicians participating in the randomized trial
All
Intervention group
P* Control Patient Physician Both
Patients
n 3,703 847 869 1,041 946
Age as of intervention date (years) 56.1  12.1 56.3  11.7 57.2  12.2 56.3  12.6 54.8  11.8 0.001
Age 65 years (% yes) 26.4 26.4 29.8 27.2 22.4§ 0.005
Sex (% female) 46.1 45.7 49.1 47.7 42.0 0.02
CAD in 12 months preintervention (% yes) 11.1 12.0 11.2 11.2 9.9 0.55
Charlson score in 12 months preintervention
(% Charlson  2) 22.3 21.5 20.5 26.2§ 20.5 0.005
Insulin use at baseline (% yes) 30.4 31.6 28.7 27.7 34.0‡ 0.01
Lipid intervention eligible (% yes) 61.9 59.3 61.9 62.8 63.2
 0.17
Glucose intervention eligible (% yes) 66.8 61.7 68.4 68.7 67.8 0.005
Preintervention A1C† 7.2 7.1 7.2§ 7.2§ 7.2 0.05
Postintervention A1C† 7.0 6.9 7.0 7.1 7.1 0.005
Preintervention LDL cholesterol† 103 104 102 102 104 0.19
Postintervention LDL cholesterol† 89 88 89 89 89 0.76
Preintervention A1C† 7.53  1.6 7.42  1.6 7.53  1.6 7.55  1.6§ 7.60  1.6§ 0.10
Postintervention A1C† 7.36  1.5 7.20  1.4 7.3  1.5§ 7.43  1.6§ 7.43  1.6 0.01
Preintervention LDL cholesterol† 108.0  31.9 108.6  31.7 107.4  32.5 106.4  31.2 109.6  32.3 0.21
Postintervention LDL cholesterol† 93.2  30.5 92.2  29.5 93.3  30.0 94.1  31.7 93.3  30.6 0.72
Physicians
n 123 32 27 37 27
Eligible patients per physician 30.1 26.5 32.2 28.1 35.0 0.27
DataaremeansSDormedian.*Omnibustestofsigniﬁcancefordifferencesacrossinterventiongroups.†Pre-andpostinterventionA1CandLDLcholesterolvalues
are the last observed values in the 12-month period before or after the intervention. ‡P  0.10; §P  0.05; P  0.01 for planned comparison of intervention group
relative to control group. CAD, coronary artery disease.
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66.0) compared with that for the control
group (Mc  76.9) among patients not
using insulin 6 months postintervention,
whereastheA1Ctestrateonlydroppedin
the physician intervention among insulin
users (Mc  76.2, Mpt  74.8, Mphys 
70.0, and Mpt  phys  74.8). There were
nosigniﬁcantdifferencesinA1Ctestrates
among groups at 12 months postinter-
vention. Among patients with preinter-
vention A1C 8%, the impact of the
intervention depended on the patient’s
age, sex, and insulin use. Patients using
insulin had higher A1C values than those
not using insulin, and their A1C values
did not differ signiﬁcantly across the four
groups (Mc  8.93, Mpt  8.70, Mphys 
9.09, and Mpt  phys  8.58), whereas
those patients not using insulin in the
three active intervention groups had
higher A1C values than those in the con-
trol group (Mc  8.04, Mpt  8.53, Mphys
 8.64, and Mpt  phys  9.08).
Among 2,547 subjects with a prein-
tervention LDL cholesterol test, LDL cho-
lesterol test rates in the 12-month
postintervention period were signiﬁ-
cantly lower for all three intervention
groupsthanforthecontrolgroup.Among
508 patients without preintervention
LDLcholesterolvalues,therewerenosig-
niﬁcant differences in postintervention
LDL cholesterol test rates (55.1%, P 
0.21; not shown). Among the 991 pa-
tients with preintervention LDL choles-
terol 100 mg/dl, those with particularly
highvaluestendedtohavehigherpostint-
ervention LDL cholesterol values, even
more so in the two provider intervention
groups. Patients in the two provider
groups who used insulin tended to have
higher LDL cholesterol values (Mphys 
109 and Mpt  phys  105) relative to the
control group (Mc  100) and patient
(Mpt  97) intervention groups, whereas
patientsinallfourgroupswhodidnotuse
insulin had equally high LDL cholesterol
values (Mc  105, Mpt  103, Mphys 
105, and Mpt  phys  105).
Table 3 presents data that reﬂect the
impactoftheinterventionsonpharmaco-
therapy intensiﬁcation in patients with
baseline LDL cholesterol 100 mg/dl
(n  1,283) or baseline A1C 7%
(n  1,037 not receiving insulin therapy;
n1,683includingthosereceivinginsu-
lin therapy). Adjusted models show no
signiﬁcant impact of any of the three in-
terventions on the likelihood of intensiﬁ-
Table 2—Impact of intervention group assignment on A1C and LDL cholesterol testing rates and values
All
Intervention group
P* Control Patient Physician Both
A1C testing rate: 1 test in 6 months (any
preintervention A1C value†)
n 3,107 715 718 895 779 Ppt  0.34
Preintervention (%) 100 100 100 100 100 Pphys  0.16
Postintervention (%) 71.2 76.6 69.2†† 70.5** 68.9†† Ppt  phys  0.10
A1C testing rate: 1 test in 12 months
(any preintervention A1C value)
n 3,107 715 718 895 779 Ppt  0.76
Preintervention (%) 100 100 100 100 100 Pphys  0.07
Postintervention (%) 86.1 87.8 87.2 85.4 84.2 Ppt  phys  0.91
A1C values (any preintervention A1C
value)
n 2,673 628 626 763 656 Ppt  0.51
Preintervention 7.47  1.5 7.39  1.5 7.47  1.5 7.49  1.5 7.52  1.5 Pphys  0.08
Postintervention 7.35  1.5 7.20  1.4 7.35  1.4 7.42  1.5** 7.41  1.6¶ Ppt  phys  0.10
Preintervention A1C 8%§
n 658 149 152 184 173 Ppt  0.81
Preintervention A1C 9.45  1.4 9.44  1.4 9.47  1.4 9.43  1.5 9.48  1.3 Pphys  0.02
Postintervention A1C 8.71  1.7 8.50  1.8 8.60  1.6†† 8.85  1.8†† 8.85  1.8‡‡ Ppt  phys  0.71
LDL cholesterol testing rate: 1 test in 12
months (any preintervention LDL
cholesterol value)§
n 2,547 614 569 716 648 Ppt  0.85
Preintervention (%) 100 100 100 100 100 Pphys  0.02
Postintervention (%) 79.3 83.2 80.1** 76.3†† 78.2†† Ppt  phys  0.10
LDL cholesterol values (mg/dl)
(preintervention LDL cholesterol 
100 mg/dl)
n 991 254 221 267 249 Ppt  0.37
Preintervention LDL cholesterol 128  26 128  25 128  28 129  27 129  26 Pphys  0.33
Postintervention LDL cholesterol 104  31 104  32 101  27 106  34 105  31 Ppt  phys  0.75
Data are means  SD or percent unless otherwise indicated. *Ppt  P value for type III patient main effect; Pphys  P value for type III physician main effect;
Ppt  phys  P value for type III patient  physician interaction. †Signiﬁcant covariate  treatment parameter: insulin use  pt. ‡Signiﬁcant covariate  treatment
parameters: age  pt, age  pt  phys, male  pt, male  phys, male  pt  phys, insulin use  pt, insulin use  phys. §Signiﬁcant covariate  treatment
parameter: male  pt. Signiﬁcant covariate  treatment parameters: LDL cholesterol  phys, age  pt, glucose eligible  phys, insulin use  phys. ¶P  0.10;
**P  0.05; ††P  0.01; ‡‡P  0.001 for planned comparison of intervention group relative to control group.
O’Connor and Associates
DIABETES CARE, VOLUME 32, NUMBER 7, JULY 2009 1161cationamongthosenotattheA1CorLDL
cholesterol goals. This result supports the
null hypothesis that the study interven-
tions did not improve quality of diabetes
care.
We assessed 12 speciﬁc deﬁned in-
stances of inappropriate pharmacother-
apy for A1C or LDL cholesterol control.
The baseline frequency of inappropriate
pharmacotherapy was low. Therefore, we
consolidated these instances into larger
categories but still found no signiﬁcant
differences related to the interventions.
Although power may be an issue here,
otherstudiessuggestedthatatthissample
size and with similar error rates, other er-
ror reduction strategies may signiﬁcantly
reduce error rates.
To help understand the main results,
we performed unplanned exploratory
analyses among patients with a preinter-
vention A1C or LDL cholesterol value
above goal. The mean  SD time to the
ﬁrst primary care visit was 52.8  63.5
days.Patientsexposedtothepatientletter
took longer to have a primary care visit
than those in the control group (hazard
ratio 0.68 [95% CI 0.55–0.85], P 
0.001). Patients in the physician treat-
ment group were also slower to have a
primary care visit (0.86 [95% CI 0.76–
0.98], P  0.03), but the interaction be-
tween patient and physician treatments
was not statistically signiﬁcant (0.68, P 
0.14).
CONCLUSIONS — In this random-
izedtrial,providingcustomizedinterven-
tions to patients and physicians 1) failed
toincreaseLDLcholesterolorA1Ctesting
rates,2)failedtoimproveLDLcholesterol
levels,3)hadadetrimentaleffectonthose
with baseline A1C 8% and a marginally
negative effect on A1C levels in subjects
with baseline A1C 7%, 4) failed to re-
duce a set of 12 risky prescribing events,
and 5) delayed time to the next primary
care visit.
Patient intervention
In a 2006 review of diabetes quality im-
provementefforts,Shojaniaetal.(20)ina
meta-regression model with adjustment
for baseline A1C and trial sample size
showedthat14controlledtrialsofpatient
reminders reduced A1C an absolute
0.11%(P0.40)and38controlledtrials
of patient education reduced A1C an ab-
solute 0.15% (P  0.20). Other reviews
also suggested only a modest impact of
patient activation or patient education in-
terventions (12,21). Some prior reports
document unanticipated or negative pa-
tientresponsestomailedclinicalinforma-
tion (22).
Analysisconﬁrmedthatpatientsinall
three intervention groups had signiﬁ-
cantly delayed time to the next primary
care visit, a visit that was advised in the
patient letters. Time to next visit was 46
days in the control group, 52 days in the
physician only intervention group, and
56 days in both groups exposed to the
patientletter.Thisdelay,contrarytowhat
we anticipated, suggests that some pa-
tients may have reacted negatively to the
letter. An alternative possibility, that pa-
tients delayed visits to work on lifestyle
changes, is not supported by the pattern
of worsening A1C values in the interven-
tion groups. Whatever the reason, a delay
in visits reduced the ability of physicians
and patients to adjust pharmacotherapy
basedontheclinicalinformationtheyhad
received.
Other features of our patient inter-
vention may have contributed to their
unexpectedly negative results. We cus-
tomized patient letters to levels of A1C
andLDLcholesterolandnotto“readiness
to change,” medication adherence, or
other behavioral patterns. Low health
literacy,innumeracy,orcognitiveimpair-
ment may have distorted the interpreta-
tion of quantitative information by some
patients (23). The information in some
patient letters may have been outdated,
discordant with previous advice, or per-
ceived as indicating that the patients were
receiving substandard care from their
current physician. Additional research is
neededtodocumentbeneﬁtsandruleout
unintended consequences of customized
mailings of clinical data to diabetic
patients.
Physician intervention
Theneedforclinicaldecisionsupportand
the desirability of customizing care to in-
dividual patients were the guiding princi-
ples of the physician intervention and are
strongly supported by the literature. Al-
though the information provided to phy-
sicians was speciﬁc for the patients under
Table 3—Impact of interventions on lipid and glucose medication initiations and titration
All
Intervention group
P† Control Patient Physician Both
Lipid moves: any hyperlipidemia medication initiation or titration
in the 12 months postintervention (preintervention LDL
cholesterol 100 mg/dl)
n 1,283 310 288 352 333 Ppt  0.39
Lipid medication preintervention (%) 49.9 47.1 51.4 54.3 46.5 Pphys  0.34
Lipid move postintervention (%) 34.7 35.2 37.5 32.4 34.2 Ppt  phys  0.88
Glucose moves: any diabetes medication initiation or titration in
the 12 months postintervention (preintervention A1C 7%)
n 1,037 207 256 317 257 Ppt  0.31
Glucose medication preintervention (%) 89.3 88.4 89.5 89.6 89.5 Pphys  0.52
Glucose move postintervention (%) 33.8 35.3 34.4 31.9 34.6 Ppt  phys  0.86
Glucose starts: any diabetes medication initiation in the 12
months postintervention (preintervention A1C 7%)
n 1,683 360 394 501 428 Ppt  0.16
Glucose medication preintervention (%) 93.4 93.3 93.1 93.4 96.7 Pphys  0.41
Glucose start postintervention (%) 18.1 19.7 18.3 17.0 17.8 Ppt  phys  0.67
*Ppt  P value for type III patient main effect; Pphys  P value for type III physician main effect; Ppt  phys  P value for type III patient  physician interaction.
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probably contributed to the failure of the
intervention. Among these was the fact
that the batched clinical data provided to
physicians was typically 6 weeks out of
datebythetimephysiciansreceiveditand
were expected to take action. A delay in
providing information on the conse-
quences of past action has signiﬁcant det-
rimental effects on how it is interpreted
and used (24). Moreover, physicians re-
ceived patient lists with decision support
every 4 months, rather than receiving the
information at the time of patient visits.
The intervention did not include ofﬁce
system redesign, team care models, or in-
centives to maximize use of the informa-
tionprovidedorassurethatpatientsmade
appointments to discuss recommended
changes in care (25).
Limitations of the study
There are a number of factors that limit
the interpretation of the data. First, the
study was conducted at a single medical
group, and results should be generalized
to other populations only with caution.
Second, the interventions were done
without the beneﬁt of EMR technology
capable of providing more up-to-date
clinical information at the point of care.
In summary, physician and patient
decision support, in the absence of a per-
sonal patient encounter, EMR support,
incentives, and ofﬁce systems designed to
support use of the information provided,
failed to improve diabetes care and wors-
ened diabetes care for many patients.
Customized patient mailings such as
those tested in this study are being widely
implemented in an unevaluated way by
many large medical groups and disease
management programs on the assump-
tion that such communications will im-
prove diabetes care. Based upon our
results, this practice should be ques-
tioned, and further efforts to substantiate
purported beneﬁts are urgently needed.
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